<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Open access : A funder's perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Kiley, R</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Promoting 21st Century Scholarly Communication, The University of Hong Kong, May 17, 2007</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2007</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/44103">http://hdl.handle.net/10722/44103</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Open Access: a funders perspective

Robert Kiley
Head of e-strategy
Wellcome Library
r.kiley@wellcome.ac.uk

Conference:
Promoting 21st Century Scholarly Communication,
University of Hong Kong, 17-18 May 2007
Overview

- Discuss why the Trust supports open access (OA)
- Provide a summary of the Trust’s OA policy and discuss how grantees can comply with this policy
- Highlight what the Trust requires when it pays an OA fee
- Provide some data on publisher compliance with the Trust’s OA policy
- Discuss the rationale behind establishing UK PMC
- Conclusion
The Wellcome Trust

- Largest charity in UK; second largest medical charity in the world
- Funds innovative biomedical research in the UK and internationally
- Currently spends around £500 million (£7.78 billion HKD) per annum – supporting the brightest scientists with the best ideas
- Supports public debate about biomedical research and its impact on health and well-being
- Home of the Wellcome Library
- More information at: http://www.wellcome.ac.uk
Why the Trust is supporting open access to the research literature

1. To improve the quality of research by maximising access to the research outputs
   - Access is still an issue – Recent exercise undertaken by the Trust showed that even researchers who has access to well-funded libraries still could not access between 10%-20% of Trust-funded research papers.
   - Research by BMC shows that 90% of NHS-funded research available online full text; 30% immediately available to public; only 40% immediately available to NHS staff. See: http://www.biomedcentral.com/openaccess/inquiry/refersubmission.pdf
Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.


Medical Research Council Laboratories, Banjul, The Gambia.

Access Denied

Access to The Journal of Infectious Diseases is restricted to registered institutional and individual subscribers.

The User ID and password you entered were incorrect. Please note that User IDs and passwords are case-sensitive. (Journal subscribers' usernames begin with uppercase "UCP".)

You were asked for a User ID and password because your http request is from an IP address not recognized by this server as belonging to a registered institutional subscriber.

Click here for more information or help with access problems.
Why the Trust is supporting open access to the research literature

1. To improve the quality of research by maximising access to the research outputs

2. To enable greater integration between the research literature and its underlying research data
   - Articles linked to gene and chemical compound datasets
   - Data mining and the semantic web - enables the extraction of new facts from the literature
Programmatic linking of text to data

Development and application of a positive-negative selectable marker system for use in reverse genetics in *Plasmodium*

Joanna A. M. Braks, Blandine Franke-Fayard, Hans Kroeze, Chris J. Janse, and Andrew P. Waters

Department of Parasitology, Center for Infectious Diseases, Leiden University Medical Centre (LUMC), The Netherlands

To whom correspondence should be addressed. Tel: +31 71 5265089; Fax: +31 71 5266207; Email: waters@lumc.nl

Received December 6, 2005, Revised February 4, 2006, Accepted February 4, 2006.

The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

ABSTRACT

A limitation of transfection of malaria parasites is the availability of only a low number of positive selectable markers for selection of transformed mutants. This is exacerbated for the rodent parasite *Plasmodium berghei* as selection of mutants is performed in vivo in laboratory rodents. We here report the development and application of a negative selection system based upon transgenic expression of a bifunctional protein (pFCU) combining yeast cytosine deaminase and uridine phosphorylase transposase (UPRT) activity in B-berahu, followed by...
Compound Summary:

CID: 3956

BioActivity: Summary
Inactive: 99 Links
Inconclusive: 2 Links

NLM Toxicology: Link

Substances:
All: 86 Links
Same: 26 Links
Mixture: 10 Links

Related Compounds:
Same, Connectivity: 2 Links

Similar Compounds: 6 Links

Medical Subject Annotations: (Total 1)

Flucytosine
A fluorinated cytosine analog that is used as an antifungal agent.

Show MeSH Tree Structure
New resources from mining the literature: textpresso

- Textpresso new text-mining system for scientific literature

Title: The Caenorhabditis elegans F-box protein SEL-10 promotes female development and may target FEM-1 and FEM-3 for degradation by the proteasome.

Author: Jager S Schwartz HT Horvitz HR Conrad B

Journal: Proceedings of the National Academy of Sciences USA Citation: V: 101 P: 12191

Abstract: The Caenorhabditis elegans F-box protein SEL-10 and its human homolog have been shown to have a role in the ubiquitin-proteasome system. The protein is a component of a multiprotein complex that targets ubiquitin- and proteasome-dependent substrates. The protein is known to be involved in the development of the nervous system, and it is believed to be involved in the control of cell death. SEL-10 is involved in the regulation of the Notch signaling pathway, which is important for the development of the nervous system.

Matching Sentences:
[ Sen. 33, subscore: 1.00 ] To obtain recombinants for LGV between N2 and CB4856, unc-76 (e911) or cdc-4 (sdc-10) (n10779) unc-76 (e911) were BIOLOGY/DEVELOPMENT: defective; CEM, cephalic companion neuron; HSN, hemisected specific neuron; SLF, polymorphism; IL, loss of function; shRNA, short-hairpin RNA; sel-10, human sel-10; SEL-10.

Supplemental links/files: reference in endnote online text related articles

Title: Heparan 2-O-sulfotransferase, hst-2, is essential for normal cell migration in Caenorhabditis elegans.

Author: Kinnunen T Huang Z Townsend J Gatdula MM Brown JR Eslie JD Turnbull JE

Journal: Proc Natl Acad Sci USA Citation: V: 102 P: 15071 YEAR: 2005 Types: A

Mapping of sel-10: sel-10 of alleles have been mapped between zap-3 and him-8 on LGV (13). The location of n777.79 was refined by using SNP mapping and the following SNPs: pkPS02, pkPS070, pkPS098, pkPS082, F55B12.9, 7581, 922, and R10D12.16.84 (12, 13).

Materials and Methods

General Methods and Strains. C. elegans strains were maintained at 20°C, unless otherwise noted. The strain n2 (Bristol) was the standard wild-type strain. For single-nucleotide polymorphism (SNP) mapping, the wild-type Hawaiian strain CB4856 was also used. The alleles, deficiencies, and duplications that were used in this study are as follows: and are described by Riddle et al. (12), except where noted otherwise: LGI, him-8(e278), n570; pwd-2(kd-2); pyf-1 and H.T.S. and H.R.H., unpublished data; LGII, aw-2(e178), c2019, e2021, e2531, and n1098; LGIII, fem-3(ab240) and c2015 and e1236; n576 and n928; LGV, fem-1(n17 and e1269), fem-3(ab236) and c2086; him-8(e1490), and ced-3(lf-17); LGV, dpy-1(e264); her-1(e162), n578 and n1739, rol-6(e240), sel-10(e41), n578, n1739 and n2605, sel-10(bc189) n1742, bc243 and n4073 (this study), sel-10(x3777); (H.T.S. and H.R.H., unpublished data), sel-10(x5834), n4041, and n4046 (B. Galván and H.R.H., unpublished data), him-8(e1490), unc-79(e171), and dpy-2(e420); and LGX, sel-12(e131) and dpy-2(e420). n5424 is a deficiency spanning the sel-10 locus (17), ced-3(e141) is a free duplication spanning the sel-10 locus (17).
New resources from mining the literature: Malaria Atlas Map

Data mined from the research literature

“Mashed-up” with Google earth
Why the Trust is supporting open access to the research literature

1. To improve the quality of research by maximising **access** to the research outputs
2. To enable greater **integration** between the research literature and its underlying research data
3. **Evaluation** purposes
   > *Is the £500m research spend funding making a difference?*
Evaluation
Why the Trust is supporting open access to the research literature

1. To improve the quality of research by maximising access to the research outputs
2. To enable greater integration between the research literature and its underlying research data
3. Evaluation purposes - is our funding making a difference?
4. Long-term preservation
   - All current articles in PMC are marked-up in XML - future-proofing the record of medicine
   - Open archive – around 2 million unique IP addresses access PMC every month – 10m page views; errors quickly spotted
OA at the Wellcome Trust: policy

All research papers – funded in whole or in part by the Wellcome Trust – must be made freely accessible from the PubMed Central and UKPMC repositories as soon as possible, and in any event within six months of the journal publisher’s official date of final publication.
How do WT grantees comply?

- Compliance can be achieved by following one of two routes:
  - Route 1
    - Publish in OA/hybrid journal [preferred route]
  - Route 2
    - Publish anywhere - but self-archive a version of the author manuscript (must include all changes that arise from the peer-review process) and make that available from PMC/UKPMC within 6 months
  - If a publisher offers neither route then
    - Author can make revision to the journals copyright statement – boilerplate language provided – and see if the publisher will accept this
    - Look for an alternative publisher
What does the Trust require when it pays an OA fee?

● Mandatory requirements
  ➢ Deposit, on behalf of the author, the final version of the article - in PMC, where it must be made freely available at the time of publication.
  ➢ Permit these articles to be freely accessed and re-used, subject to agreed limits (for example, the commercial rights to the article would most likely continue to reside with the publisher).
  ➢ Allow such articles to be mirrored to PMC International repositories, such as UKPMC.
  ➢ Deposit the article in XML, along with high-resolution images used in the article.
  ➢ Sign PMC Selective Deposit Agreement

● Desirable requirements
  ➢ Deposit the publisher PDF version of the article in PMC.
  ➢ Make the article freely available on the publisher website at the time of publication
Publishers response to the Wellcome grant conditions

- Significant number of commercial and not-for-profit publishers now offer an OA option that is fully compliant with the Trust’s requirements (e.g. PLoS, BMC, Springer, Elsevier, OUP, CUP, BMJPG, Sage, Taylor & Francis)
- Other publishers allow the author to self-archive a version of the final article and make that available within 6 months (e.g. Nature, AAAS, AMA, Am. Physiological Assoc)
- However, some publishers have policies that do not allow Wellcome-funded authors to publish in these titles
  - High profile publishers that do not offer a WT-compliant policy include the American Association of Immunologists, and the American Association for Cancer Research
Biomedical publishers: compliance with Wellcome OA policy

Source = RoMEO database
PubMed 4000 study analysed papers indexed by PubMed, and attributed to WT funding, and looked to see if these were published in journals that had a WT-compliant policy.
Are Wellcome grantee’s adhering to the mandate?

- Too early to tell. Policy has only been fully implemented since October 2006
  - Pragmatic approach. If papers were “in process” before 1st October, and the journal that accepted the paper is now deemed non-compliant – the Trust does not expect the researcher to withdraw a manuscript.
  - Obviously, all new papers, submitted for publication after Oct 2006, should only be submitted to “WT-compliant” journals

- Some encouraging signs….
  - In the first 3 months of running UKPMC 250 author manuscripts were deposited and completed
  - Elsevier have deposited 35 papers within the past month

- ..but more advocacy and awareness required
  - Only 22% of OA funds made available to UK universities in the year 05-06 has been claimed.
Total cost of paying for OA?

- Just funding the research is a job only part done – a fundamental part of our mission is to ensure the widest possible dissemination and unrestricted access to that research.
- Trust estimates that providing OA to all the research papers it helps fund will cost between 1%-2% of its annual research budget.

  Approx 4000 original research papers published every year. If every single one of those papers was published as an open access article, with an average cost of £1650 per article, the total cost to the Trust would be £6.64 million; just over 1% of our annual research budget.

  Trust is rarely the sole funder of a research team, and more than 80% of papers that acknowledge our support also acknowledge the support of one or more other funders. In time these costs will be spread throughout the research budget and fall below the figure estimated here.
Objective is to create a stable, permanent and free-to-access online digital archive of the full-text, peer reviewed research publications (and datasets) that arise from research funded by the UKPMC Funders Group.

8 UK biomedical research funding organisations have joined the UKPMC Funders Group.

Estimated that around 90% of the biomedical research that is funded in the UK comes from the UKPMC funders.
# UKPMC Funders Group

<table>
<thead>
<tr>
<th>Funder</th>
<th>Mandate?</th>
<th>Max embargo</th>
<th>OA – Article Processing Charges (APC)?</th>
</tr>
</thead>
<tbody>
<tr>
<td>arc</td>
<td>✓</td>
<td>6 mo.</td>
<td>Will pay APC’s via grants.</td>
</tr>
<tr>
<td>BBSRC</td>
<td>✓</td>
<td>ASAP</td>
<td>Will pay APC’s via grants.</td>
</tr>
<tr>
<td>BHF</td>
<td>✓</td>
<td>6 mo.</td>
<td>Will pay APC’s via additional funds</td>
</tr>
<tr>
<td>CSO (Scot)</td>
<td>✓</td>
<td>6 mo.</td>
<td>APC can be paid from grant funds, but will not be specifically allocated.</td>
</tr>
<tr>
<td>CR-UK</td>
<td>✓</td>
<td>6 mo.</td>
<td>APC costs to be met from existing grants/lab budget allocations.</td>
</tr>
<tr>
<td>Dept Health</td>
<td>✓</td>
<td>6 mo.</td>
<td>Will pay APC’s via grants.</td>
</tr>
<tr>
<td>MRC</td>
<td>✓</td>
<td>6 mo.</td>
<td>Will pay APC’s via grants.</td>
</tr>
<tr>
<td>Wellcome Trust</td>
<td>✓</td>
<td>6 mo.</td>
<td>Will pay APC’s via additional funds.</td>
</tr>
</tbody>
</table>
Why establish UK version of PMC?

- Provides the infrastructure to enable Wellcome grantees (and others within the UKPMC Funders Group) to comply with their grant conditions
- A UK version of PMC will benefit the Trust, its partners and the UK research community in a number ways:
  - *UK-focussed services - evaluation of funding; development of new metrics that could feed into a future RAE*
  - *Local ingestion of UK documents e.g. NICE guidelines, MRC reports*
  - *Enhanced functionality - integration with grants systems, text mining services with other open data sources*
  - *Long term preservation of the record of medicine becomes a shared responsibility*
  - *Helps to ensure that the OA principles espoused by the Trust become a reality in the UK*
UKPMC – systems and services

- **Systems**
  - A UK-hosted mirror of PMC
  - A manuscript submission and tracking system for UKPMC grantees

- **Services**
  - Robust, secure and scaleable infrastructure
  - Manuscript conversion facilities
  - Helpdesk
  - Communications and marketing
  - R&D

- Contract to run and develop UKPMC services has been awarded to a consortium led by the British Library in association with University of Manchester and European Bioinformatics Institute

- UKPMC went live in January 2007 – see [http://ukPMC.ac.uk](http://ukpmc.ac.uk)
Conclusion

- They way original research papers are disseminated and made available is changing.
  - Funders are demanding more; publishers are responding to this need
- In the UK, biomedical research funders have agreed a common approach to OA, and now have the infrastructure in place (UKPMC) to help realise our objectives.
- Dissemination costs are research costs
- “Ensuring that the outputs of research are freely available to all is the best way to maximise their utility.” Sir John Sulston, 2006.